Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine

开发专有噬菌体Qbeta作为抗沙门氏菌疫苗的疫苗载体平台

• 批准号: 10448433
• 负责人: Herbert Wanjala Kavunja
• 金额: $ 29.46万
• 依托单位: IASO THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-09 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10448433
• 关键词: Address; Antibodies; Antibody Response; Antigen Targeting; Antigens; Bacteriophages; Benchmarking; Biotechnology; COVID-19 pandemic; Carbohydrates; Cell surface; Centers for Disease Control and Prevention (U.S.); Cessation of life; Characteristics; Chemosensitization; Clinical; Clinical Data; Clinical Research; Communicable Diseases; Conjugate Vaccines; Development; Disease; Drug resistance; Epitopes; Escherichia coli EHEC; Escherichia coli O157; Food Poisoning; Future; Genetic Engineering; Health; Helper-Inducer T-Lymphocyte; Human; Immune; Immune response; Immune system; Immunize; Immunoglobulin G; Incidence; Infection; Intellectual Property; Licensing; Malignant Neoplasms; Mediation; Michigan; Multi-Drug Resistance; Mus; Pain; Pathogenicity; Pathologic; Phase; Polysaccharides; Process; Production; Protocols documentation; Reproducibility; Safety; Salmonella; Salmonella Vaccines; Salmonella infections; Salmonella paratyphi; Salmonella typhi; Salmonella typhimurium; Savings; Small Business Innovation Research Grant; Societies; System; T-Lymphocyte Epitopes; Technology; Therapeutic; Universities; Vaccine Antigen; Vaccine Design; Vaccines; Vertebral column; Virus-like particle; analytical method; base; biomaterial compatibility; cross reacting material 197; design; fighting; foodborne illness; head-to-head comparison; immunogenic; immunogenicity; mouse model; mutant; next generation; novel; novel vaccines; pre-clinical; protective efficacy; side effect; tool; vaccine access; vaccine candidate; vaccine development; vaccine efficacy; vaccine platform; vaccine safety

Project summary Vaccines have saved millions of lives. However, there are many diseases against which vaccines are not yet available, with the current COVID-19 pandemic in the world serving as a painful reminder of the need for vaccines against emerging diseases. With the growing emphasis on vaccine safety, next-generation vaccine designs have been increasingly focusing on subunit antigens. Because subunit epitopes tend to have lower immunogenicity, immunogenic carriers are critical to deliver the desired antigen to the immune system and to enhance the immune responses. However, there are very few carriers available that have been validated in clinical studies. In this SBIR phase I project, Iaso Therapeutics, Inc. will focus on the development of a proprietary bacteriophage mutant Qβ (mQβ) virus like particle as a platform technology for conjugate vaccines. In aim 1, robust protocols will be established for expression, purification, and long-term storage of mQβ. In addition, head to head comparison will be performed to demonstrate that mQβ can elicit higher levels of antibodies as compared to current benchmark carriers. In aim 2, the powerful mQβ platform will be applied to deliver Salmonella associated glycans as potential vaccines against multiple strains of common pathogenic Salmonella. The vaccine will be optimized to enhance protection from Salmonella infection. When successfully developed, this project will establish mQβ as an attractive immunogenic carrier for vaccine development and provide important pre-clinical data for anti-Salmonella vaccines.

项目摘要 疫苗挽救了数百万的生命。但是，有许多疾病没有疫苗 然而可用，世界目前的Covid-19世界大流行充满了痛苦的提醒 针对新兴疾病的疫苗。随着对疫苗安全的越来越重视下一代疫苗 设计越来越关注亚基抗原。因为亚基表位往往较低 免疫原性，免疫原性载体对于将所需的抗原传递到免疫系统和至关重要 增强免疫反应。但是，很少有可用的运营商在 临床研究。在SBIR I阶段项目中，IASO Therapeutics，Inc。将重点放在专有的开发上 噬菌体突变体Qβ（MQβ）病毒（如颗粒）作为一种偶联疫苗的平台技术。在AIM 1中， 将建立强大的方案以表达，纯化和长期存储MQβ。此外，头 要进行比较，将进行比较，以证明MQβ可以在比较中引起更高水平的抗体 到当前的基准载体。在AIM 2中，功能强大的MQβ平台将用于提供沙门氏菌 相关的聚糖作为对多种常见致病沙门氏菌菌株的潜在疫苗。这 疫苗将被优化以增强沙门氏菌感染的保护。成功开发时， 项目将建立MQβ作为疫苗开发的有吸引力的免疫原性载体，并提供重要的 抗盐酸疫苗的临床前数据。